NCT01489943 - A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2011

Primary Completion Date

November 10, 2011

Study Completion Date

November 10, 2011

Conditions

Crohn's Disease

Interventions

DRUG

GSK1605786 500 mg

Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.

DRUG

Midazolam 3 mg

Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.

DRUG

Pioglitazone 15 mg

Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.

DRUG

Omeprazole 40 mg

Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.

DRUG

Rosuvastatin 10 mg

Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.

Trial Locations (1)

14202

GSK Investigational Site, Buffalo